Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:
Roche Holdings Ltd ADR (RHHBY)
Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Investor Brand Network - Thu Sep 21, 9:29AM CDT

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.3735 (-6.18%)
RHHBY : 34.2000 (+0.50%)
JAZZ : 131.23 (-1.38%)
ALXO : 4.76 (-3.64%)
ACHL : 0.9250 (+5.14%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Investor Brand Network - Wed Sep 20, 9:38AM CDT

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 0.3735 (-6.18%)
RHHBY : 34.2000 (+0.50%)
JAZZ : 131.23 (-1.38%)
ALXO : 4.76 (-3.64%)
ACHL : 0.9250 (+5.14%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation FinancialNewsMedia - Wed Sep 20, 7:30AM CDT

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 0.3735 (-6.18%)
RHHBY : 34.2000 (+0.50%)
JAZZ : 131.23 (-1.38%)
ALXO : 4.76 (-3.64%)
ACHL : 0.9250 (+5.14%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation PR Newswire - Wed Sep 20, 7:30AM CDT

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 34.2000 (+0.50%)
GNPX : 0.3735 (-6.18%)
JAZZ : 131.23 (-1.38%)
ALXO : 4.76 (-3.64%)
ACHL : 0.9250 (+5.14%)
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street Motley Fool - Tue Sep 12, 4:14AM CDT

Find out why analysts have such high expectations for these stocks.

RHHBY : 34.2000 (+0.50%)
RXRX : 7.78 (+2.77%)
BLUE : 3.06 (-0.65%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030 FinancialNewsMedia - Fri Sep 8, 7:45AM CDT

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.9000 (+1.06%)
ALC : 76.74 (-0.18%)
BLCO : 16.81 (-1.41%)
JNJ : 157.11 (-1.20%)
RHHBY : 34.2000 (+0.50%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030 PR Newswire - Fri Sep 8, 7:45AM CDT

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.9000 (+1.06%)
ALC : 76.74 (-0.18%)
BLCO : 16.81 (-1.41%)
JNJ : 157.11 (-1.20%)
RHHBY : 34.2000 (+0.50%)
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare PR Newswire - Tue Sep 5, 12:00AM CDT

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals...

RHHBY : 34.2000 (+0.50%)
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Newswire.ca - Tue Sep 5, 12:00AM CDT

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals...

RHHBY : 34.2000 (+0.50%)
Is Regeneron Pharmaceuticals Still a Top Growth Stock? Motley Fool - Mon Aug 21, 5:30AM CDT

The biotech's focus on innovation could be a boon for shareholders.

SNY : 52.97 (-2.25%)
NTLA : 32.09 (-0.80%)
RHHBY : 34.2000 (+0.50%)
REGN : 832.66 (+0.03%)

Barchart Exclusives

3 Tech Stocks to Buy Now for Q4 Barchart - 1 hour ago
Looking to bolster your tech portfolio? Here are three stocks that have pulled back with the broader market in September, but look poised for growth going forward. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot